PsilOpioid: psilocybin therapy in opioid use disorder
Proof-of-concept randomised controlled trial of psilocybin therapy and brain reward mechanisms in opioid use disorder. Condition: Opioid use disorder. Sponsor/lead site: Imperial College London (NIHR Imperial Clinical Research Facility). Funder: National Institute for Health and Care Research. Recruitment window on ISRCTN: 13 Nov 2025 – 6 Jan 2027.
Trial listings come from public registries. Taking part is up to the study team, who will check your eligibility. Recruitment status can change at any time, so check the registry record first. See also: UK psilocybin trials and is psychedelic therapy legal in the UK?
- Type
- Recruiting trial
- Location
- London, United Kingdom
- Status
- Recruitment window open (ISRCTN)
- Registry
- ISRCTN · ISRCTN10232579
- Sponsor
- Imperial College London (NIHR Imperial Clinical Research Facility)
- Condition
- Opioid use disorder
- Website
- https://www.isrctn.com/ISRCTN10232579
- Source
- https://www.isrctn.com/ISRCTN10232579
- Last verified
- 23 October 2026
About this directory. Psyche Insights lists organisations for information only. A listing is not an endorsement, a recommendation or medical advice, and we do not take referral fees. We list only lawful, regulated services, registered clinical trials and professional training. We do not list retreats or anyone offering psychedelics outside the law. Psilocybin, MDMA, LSD and DMT are controlled drugs in the UK. Eligibility, availability and legal status differ by country and change often. Always check details with the provider or trial team, and talk to your GP or specialist before making any treatment decision. Paid placements are labelled “Featured · Paid placement” and never change our editorial descriptions. See our terms.
Corrections and removal. Spotted an error, or represent a listed organisation and want a listing corrected, updated or removed? Email [email protected] with the page link and the change needed. We aim to reply within 5 working days.
Follow access news each week
New trials, approvals and access routes, UK and Europe first.
Subscribe free →